ArticleFrontiers in oncology2025
Case Report: Blood single-cell analysis of a IVB high-grade serous ovarian cancer patient presenting a favorable prognosis.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High-grade serous ovarian cancer (HGSOC) diagnosed at stage IVB typically carries a poor prognosis. Here, we describe a rare case of with an exceptional and sustained response to therapy. To explore potential drivers of this favorable outcome, we combined clinical evaluation with molecular profiling of liquid biopsy samples. Methods: We employed a multi-platform liquid biopsy approach in peripheral blood samples collected preoperatively. Bulk RNA sequencing was performed on platelet RNA, while single-cell RNA sequencing (scRNA-seq) profiled peripheral blood mononuclear cells (PBMCs). Additionally, circulating tumor cells were identified using imaging flow cytometry (imFC). Results: Single-cell transcriptomic analysis identified two candidate CTCs (Circulating Tumor Cells): one with an epithelial phenotype and another with a hybrid epithelial-mesenchymal (EMT) phenotype. The EMT CTC showed upregulation of IL12A, genes involved in the mTOR pathway (RPTOR, RICTOR, MTOR), and DNA repair, while the epithelial CTC expressed high levels of VEGFA. ImFC-based assay identified one putative mesenchymal-like CTC. Platelet RNA analysis revealed downregulation of ribosomal genes and upregulation of genes related to cytoskeletal remodeling and adhesion. ANGPT1 was downregulated, while AKT1 were upregulated, putatively indicating mTOR pathway activation. Glycolytic enzymes PKM and PGK1 were strongly upregulated, and reduced expression of DDIT4, HIF1A, CSF2RA, and CSF3R suggested altered stress and cytokine signaling. Conclusion: This integrative molecular and phenotypic profiling of blood-derived components identified potentially distinct molecular signatures, such as overexpression of IL12, ANGPT1 downregulation and HIF1A downregulation, in the literature described as linked to the patient's beneficial prognosis. These findings suggest that advanced liquid biopsy techniques may provide complementary insights into prognostic biomarkers and therapeutic targets in HGSOC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.